Cynthia Anne Leifer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Cynthia Anne Leifer has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Annapoorani Chockalingam
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
4 shared publications- Erika J. Gruber
Department of Population Health and Pathobiology, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USA
4 shared publications James C. Brooks
Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853; and Glycobia Inc., Ithaca, NY 14853
4 shared publicationsJody Cameron
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
3 shared publicationsMaroof Hasan
Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA
3 shared publicationsChia-Hsin Ju
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University , Ithaca, NY 14853
2 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. -1 (aop) , 1-11
Toward creating “caninized” mice: reconstitution of canine immune cells in immunodeficient mice
Objective: To generate “caninized” mice that could be used for investigating canine diseases and testing new therapies. Methods: In this experimental study, canine hematopoietic stem cells (HSCs) were isolated from bone marrow mononuclear cells from donor dogs using immunomagnetic sorting and an anti-canine CD34 antibody. Fresh or overnight-cultured HSCs were administered IV into sublethally irradiated immunodeficient mice (NOD scid γ strain) 4 to 20 hours after irradiation (median dose, 2.0 X 10 5 cells; n = 120) with noninjected irradiated controls (30). Engraftment was assessed by serum canine immunoglobulin M (IgM) measurement and flow cytometric analysis for canine leukocytes and immunohistochemical staining for T and B cells. Results: HSCs were enriched after sorting (median CD34 + cells, 87.6% vs 2.5% in bone marrow mononuclear cells). Canine IgM was measurable in sera of 49% of 94 surviving injected mice 19 to 42 weeks after irradiation (median IgM, 310 ng/mL; range, 18 to > 8,400 ng/mL). Higher serum canine IgM concentrations were detected in mice injected with fresh versus overnight-cultured HSCs. Low numbers of canine leukocytes and T and B cells were identified in the spleen and bone marrow with flow cytometry or immunohistochemistry. Conclusions: NOD scid γ mice can be engrafted with canine immune cells. Clinical Relevance: The creation of “caninized” mice is feasible, but efficiency of engraftment was low and requires further optimization before these mice can be used to model canine disease.
- 26 May 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. -1 (aop) , 1-11
Open AccessToward creating “caninized” mice: reconstitution of canine immune cells in immunodeficient mice
Objective: To generate “caninized” mice that could be used for investigating canine diseases and testing new therapies. Methods: In this experimental study, canine hematopoietic stem cells (HSCs) were isolated from bone marrow mononuclear cells from donor dogs using immunomagnetic sorting and an anti-canine CD34 antibody. Fresh or overnight-cultured HSCs were administered IV into sublethally irradiated immunodeficient mice (NOD scid γ strain) 4 to 20 hours after irradiation (median dose, 2.0 X 10 5 cells; n = 120) with noninjected irradiated controls (30). Engraftment was assessed by serum canine immunoglobulin M (IgM) measurement and flow cytometric analysis for canine leukocytes and immunohistochemical staining for T and B cells. Results: HSCs were enriched after sorting (median CD34 + cells, 87.6% vs 2.5% in bone marrow mononuclear cells). Canine IgM was measurable in sera of 49% of 94 surviving injected mice 19 to 42 weeks after irradiation (median IgM, 310 ng/mL; range, 18 to > 8,400 ng/mL). Higher serum canine IgM concentrations were detected in mice injected with fresh versus overnight-cultured HSCs. Low numbers of canine leukocytes and T and B cells were identified in the spleen and bone marrow with flow cytometry or immunohistochemistry. Conclusions: NOD scid γ mice can be engrafted with canine immune cells. Clinical Relevance: The creation of “caninized” mice is feasible, but efficiency of engraftment was low and requires further optimization before these mice can be used to model canine disease.
- Open Access
- 18 August 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116157
Gut commensal microbiota drive tailored macrophage responses
- 18 August 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (8) , 116157
Open AccessGut commensal microbiota drive tailored macrophage responses
- Open Access
- 1 January 2025
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 86 (1) , 1-10
Generation of primary feline chimeric antigen receptor T cells
OBJECTIVE: The purpose of this study was to develop procedures to engineer feline chimeric antigen receptor (CAR) T cells. METHODS: 6 healthy cats were used in this study. Blood was collected, and CD3+ primary T cells were enriched by magnetic activated cell sorting, expanded, and used to generate CAR T cells. RESULTS: Phorbol myristate acetate plus ionomycin and concanavalin A induced similar early proliferation of CD3-enriched feline CD4+ and CD8+ T cells but phorbol myristate acetate plus ionomycin induced greater expansion over 12 days. Chimeric antigen receptor T cells were engineered by transduction with an FIV-based lentiviral system to express a human CD19 CAR. Feline CD19 CAR T cells demonstrated specific cytotoxicity against human CD19+ target cells. Conditions were developed to polarize the T cells to THelper subsets. CONCLUSIONS: We generated functional and specific primary feline CAR T cells and demonstrated conditions to polarize the cells, which may be therapeutically advantageous for CAR T-cell use in a variety of disease contexts. CLINICAL RELEVANCE: CAR T therapy has been used with great success for human hematologic malignancies and is under development for use in canines. Our study is the first demonstration of functional feline CAR T cells and describes the procedures for their engineering. These findings lay the foundation for future development of CAR T therapy for multiple feline diseases.
- 1 January 2025
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 86 (1) , 1-10
Open AccessGeneration of primary feline chimeric antigen receptor T cells
OBJECTIVE: The purpose of this study was to develop procedures to engineer feline chimeric antigen receptor (CAR) T cells. METHODS: 6 healthy cats were used in this study. Blood was collected, and CD3+ primary T cells were enriched by magnetic activated cell sorting, expanded, and used to generate CAR T cells. RESULTS: Phorbol myristate acetate plus ionomycin and concanavalin A induced similar early proliferation of CD3-enriched feline CD4+ and CD8+ T cells but phorbol myristate acetate plus ionomycin induced greater expansion over 12 days. Chimeric antigen receptor T cells were engineered by transduction with an FIV-based lentiviral system to express a human CD19 CAR. Feline CD19 CAR T cells demonstrated specific cytotoxicity against human CD19+ target cells. Conditions were developed to polarize the T cells to THelper subsets. CONCLUSIONS: We generated functional and specific primary feline CAR T cells and demonstrated conditions to polarize the cells, which may be therapeutically advantageous for CAR T-cell use in a variety of disease contexts. CLINICAL RELEVANCE: CAR T therapy has been used with great success for human hematologic malignancies and is under development for use in canines. Our study is the first demonstration of functional feline CAR T cells and describes the procedures for their engineering. These findings lay the foundation for future development of CAR T therapy for multiple feline diseases.
- Open Access
- 17 February 2023
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10, 1130182
Racing CARs to veterinary immuno-oncology
Chimeric antigen receptors (CARs) have demonstrated remarkable promise in human oncology over the past two decades, yet similar strategies in veterinary medicine are still in development. CARs are synthetically engineered proteins comprised of a specific antigen-binding single chain variable fragment (ScFv) fused to the signaling domain of a T cell receptor and co-receptors. Patient T cells engineered to express a CAR are directed to recognize and kill target cells, most commonly hematological malignancies. The U.S Food and Drug Administration (FDA) has approved multiple human CAR T therapies, but translation of these therapies into veterinary medicine faces many challenges. In this review, we discuss considerations for veterinary use including CAR design and cell carrier choice, and discuss the future promise of translating CAR therapy into veterinary oncology.
- 17 February 2023
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 10, 1130182
Open AccessRacing CARs to veterinary immuno-oncology
Chimeric antigen receptors (CARs) have demonstrated remarkable promise in human oncology over the past two decades, yet similar strategies in veterinary medicine are still in development. CARs are synthetically engineered proteins comprised of a specific antigen-binding single chain variable fragment (ScFv) fused to the signaling domain of a T cell receptor and co-receptors. Patient T cells engineered to express a CAR are directed to recognize and kill target cells, most commonly hematological malignancies. The U.S Food and Drug Administration (FDA) has approved multiple human CAR T therapies, but translation of these therapies into veterinary medicine faces many challenges. In this review, we discuss considerations for veterinary use including CAR design and cell carrier choice, and discuss the future promise of translating CAR therapy into veterinary oncology.
- Open Access
- 16 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260756
Macrophage uptake of oxidized and acetylated low-density lipoproteins and generation of reactive oxygen species are regulated by linear stiffness of the growth surface
Macrophages are key players in the development of atherosclerosis: they scavenge lipid, transform into foam cells, and produce proinflammatory mediators. At the same time, the arterial wall undergoes profound changes in its mechanical properties. We recently showed that macrophage morphology and proinflammatory potential are regulated by the linear stiffness of the growth surface. Here we asked whether linear stiffness also regulates lipid uptake by macrophages. We cultured murine bone marrow-derived macrophages (BMMs) on polyacrylamide gels modeling stiffness of healthy (1kPa) and diseased (10-150kPa) blood vessels. In unprimed BMMs, increased linear stiffness increased uptake of oxidized (oxLDL) and acetylated (acLDL) low density lipoproteins and generation of reactive oxygen species, but did not alter phagocytosis of bacteria or silica particles. Macrophages adapted to stiff growth surfaces had increased mRNA and protein expression of two key lipoprotein receptors: CD36 and scavenger receptor b1. Regulation of the lipoprotein receptor, lectin-like receptor for ox-LDL, was more complex: mRNA expression decreased but surface protein expression increased with increased stiffness. Focal adhesion kinase was required for maximal uptake of oxLDL, but not of acLDL. Uptake of oxLDL and acLDL was independent of rho-associated coiled coil kinase. Through pharmacologic inhibition and genetic deletion, we found that transient receptor potential vanilloid 4 (TRPV4), a mechanosensitive ion channel, plays an inhibitory role in the uptake of acLDL, but not oxLDL. Together, these results implicate mechanical signaling in the uptake of acLDL and oxLDL, opening up the possibility of new pharmacologic targets to modulate lipid uptake by macrophages in vivo.
- 16 December 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260756
Open AccessMacrophage uptake of oxidized and acetylated low-density lipoproteins and generation of reactive oxygen species are regulated by linear stiffness of the growth surface
Macrophages are key players in the development of atherosclerosis: they scavenge lipid, transform into foam cells, and produce proinflammatory mediators. At the same time, the arterial wall undergoes profound changes in its mechanical properties. We recently showed that macrophage morphology and proinflammatory potential are regulated by the linear stiffness of the growth surface. Here we asked whether linear stiffness also regulates lipid uptake by macrophages. We cultured murine bone marrow-derived macrophages (BMMs) on polyacrylamide gels modeling stiffness of healthy (1kPa) and diseased (10-150kPa) blood vessels. In unprimed BMMs, increased linear stiffness increased uptake of oxidized (oxLDL) and acetylated (acLDL) low density lipoproteins and generation of reactive oxygen species, but did not alter phagocytosis of bacteria or silica particles. Macrophages adapted to stiff growth surfaces had increased mRNA and protein expression of two key lipoprotein receptors: CD36 and scavenger receptor b1. Regulation of the lipoprotein receptor, lectin-like receptor for ox-LDL, was more complex: mRNA expression decreased but surface protein expression increased with increased stiffness. Focal adhesion kinase was required for maximal uptake of oxLDL, but not of acLDL. Uptake of oxLDL and acLDL was independent of rho-associated coiled coil kinase. Through pharmacologic inhibition and genetic deletion, we found that transient receptor potential vanilloid 4 (TRPV4), a mechanosensitive ion channel, plays an inhibitory role in the uptake of acLDL, but not oxLDL. Together, these results implicate mechanical signaling in the uptake of acLDL and oxLDL, opening up the possibility of new pharmacologic targets to modulate lipid uptake by macrophages in vivo.
- Open Access
- 19 January 2020
- Published by SAGE Publications in Innate Immunity
- Vol. 26 (1) , 15-25
Molecular regulation of TLR signaling in health and disease: mechano-regulation of macrophages and TLR signaling
Immune cells encounter tissues with vastly different biochemical and physical characteristics. Much of the research emphasis has focused on the role of cytokines and chemokines in regulating immune cell function, but the role of the physical microenvironment has received considerably less attention. The tissue mechanics, or stiffness, of healthy tissues varies dramatically from soft adipose tissue and brain to stiff cartilage and bone. Tissue mechanics also change due to fibrosis and with diseases such as atherosclerosis or cancer. The process by which cells sense and respond to their physical microenvironment is called mechanotransduction. Here we review mechanotransduction in immunologically important diseases and how physical characteristics of tissues regulate immune cell function, with a specific emphasis on mechanoregulation of macrophages and TLR signaling.
- 19 January 2020
- Published by SAGE Publications in Innate Immunity
- Vol. 26 (1) , 15-25
Open AccessMolecular regulation of TLR signaling in health and disease: mechano-regulation of macrophages and TLR signaling
Immune cells encounter tissues with vastly different biochemical and physical characteristics. Much of the research emphasis has focused on the role of cytokines and chemokines in regulating immune cell function, but the role of the physical microenvironment has received considerably less attention. The tissue mechanics, or stiffness, of healthy tissues varies dramatically from soft adipose tissue and brain to stiff cartilage and bone. Tissue mechanics also change due to fibrosis and with diseases such as atherosclerosis or cancer. The process by which cells sense and respond to their physical microenvironment is called mechanotransduction. Here we review mechanotransduction in immunologically important diseases and how physical characteristics of tissues regulate immune cell function, with a specific emphasis on mechanoregulation of macrophages and TLR signaling.
- Open Access
- 1 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (3) , eaav9788
Immunomodulatory nanogels overcome restricted immunity in a murine model of gut microbiome–mediated metabolic syndrome
Biomaterials-based nanovaccines, such as those made of poly(lactic-co-glycolic acid) (PLGA), can induce stronger immunity than soluble antigens in healthy wild-type mouse models. However, whether metabolic syndrome can influence the immunological responses of nanovaccines remains poorly understood. Here, we first show that alteration in the sensing of the gut microbiome through Toll-like receptor 5 (TLR5) and the resulting metabolic syndrome in TLR5−/− mice diminish the germinal center immune response induced by PLGA nanovaccines. The PLGA nanovaccines, unexpectedly, further changed gut microbiota. By chronically treating mice with antibiotics, we show that disrupting gut microbiome leads to poor vaccine response in an obesity-independent manner. We next demonstrate that the low immune response can be rescued by an immunomodulatory Pyr-pHEMA nanogel vaccine, which functions through TLR2 stimulation, enhanced trafficking, and induced stronger germinal center response than alum-supplemented PLGA nanovaccines. The study highlights the potential for immunomodulation under gut-mediated metabolic syndrome conditions using advanced nanomaterials.
- 1 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (3) , eaav9788
Open AccessImmunomodulatory nanogels overcome restricted immunity in a murine model of gut microbiome–mediated metabolic syndrome
Biomaterials-based nanovaccines, such as those made of poly(lactic-co-glycolic acid) (PLGA), can induce stronger immunity than soluble antigens in healthy wild-type mouse models. However, whether metabolic syndrome can influence the immunological responses of nanovaccines remains poorly understood. Here, we first show that alteration in the sensing of the gut microbiome through Toll-like receptor 5 (TLR5) and the resulting metabolic syndrome in TLR5−/− mice diminish the germinal center immune response induced by PLGA nanovaccines. The PLGA nanovaccines, unexpectedly, further changed gut microbiota. By chronically treating mice with antibiotics, we show that disrupting gut microbiome leads to poor vaccine response in an obesity-independent manner. We next demonstrate that the low immune response can be rescued by an immunomodulatory Pyr-pHEMA nanogel vaccine, which functions through TLR2 stimulation, enhanced trafficking, and induced stronger germinal center response than alum-supplemented PLGA nanovaccines. The study highlights the potential for immunomodulation under gut-mediated metabolic syndrome conditions using advanced nanomaterials.
- Open Access
- 18 April 2018
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 30 (6) , 267-278
Toll-like receptor signaling in macrophages is regulated by extracellular substrate stiffness and Rho-associated coiled-coil kinase (ROCK1/2)
Macrophages participate in immunity, tissue repair and tissue homeostasis. Activation of Toll-like receptors (TLRs) by conserved exogenous or endogenous structures initiates signaling cascades that result in the release of cytokines such as tumor necrosis factor α (TNFα). Extracellular substrate stiffness is known to regulate functions of non-immune cells through a process called mechanotransduction, yet less is known about how physical cues affect macrophage function or TLR signaling. To investigate this question, we cultured murine primary bone marrow-derived macrophages (BMMs) and RAW264.7 cells on fibronectin-coated polyacrylamide (PA) gels of defined stiffnesses (1, 20 and 150 kPa) that approximate the physical properties of physiologic tissues. BMMs on all gels were smaller and more circular than those on rigid glass. Macrophages on intermediate stiffness 20 kPa PA gels were slightly larger and less circular than those on either 1 or 150 kPa. Secretion of the pro-inflammatory cytokine, TNFα, in response to stimulation of TLR4 and TLR9 was increased in macrophages grown on soft gels versus more rigid gels, particularly for BMMs. Inhibition of the rho-associated coiled-coil kinase 1/2 (ROCK1/2), key mediators in cell contractility and mechanotransduction, enhanced release of TNFα in response to stimulation of TLR4. ROCK1/2 inhibition enhanced phosphorylation of the TLR downstream signaling molecules, p38, ERK1/2 and NFκB. Our data indicate that physical cues from the extracellular environment regulate macrophage morphology and TLR signaling. These findings have important implications in the regulation of macrophage function in diseased tissues and offer a novel pharmacological target for the manipulation of macrophage function in vivo.
- 18 April 2018
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 30 (6) , 267-278
Open AccessToll-like receptor signaling in macrophages is regulated by extracellular substrate stiffness and Rho-associated coiled-coil kinase (ROCK1/2)
Macrophages participate in immunity, tissue repair and tissue homeostasis. Activation of Toll-like receptors (TLRs) by conserved exogenous or endogenous structures initiates signaling cascades that result in the release of cytokines such as tumor necrosis factor α (TNFα). Extracellular substrate stiffness is known to regulate functions of non-immune cells through a process called mechanotransduction, yet less is known about how physical cues affect macrophage function or TLR signaling. To investigate this question, we cultured murine primary bone marrow-derived macrophages (BMMs) and RAW264.7 cells on fibronectin-coated polyacrylamide (PA) gels of defined stiffnesses (1, 20 and 150 kPa) that approximate the physical properties of physiologic tissues. BMMs on all gels were smaller and more circular than those on rigid glass. Macrophages on intermediate stiffness 20 kPa PA gels were slightly larger and less circular than those on either 1 or 150 kPa. Secretion of the pro-inflammatory cytokine, TNFα, in response to stimulation of TLR4 and TLR9 was increased in macrophages grown on soft gels versus more rigid gels, particularly for BMMs. Inhibition of the rho-associated coiled-coil kinase 1/2 (ROCK1/2), key mediators in cell contractility and mechanotransduction, enhanced release of TNFα in response to stimulation of TLR4. ROCK1/2 inhibition enhanced phosphorylation of the TLR downstream signaling molecules, p38, ERK1/2 and NFκB. Our data indicate that physical cues from the extracellular environment regulate macrophage morphology and TLR signaling. These findings have important implications in the regulation of macrophage function in diseased tissues and offer a novel pharmacological target for the manipulation of macrophage function in vivo.
- 1 February 2017
- Published by Elsevier in Seminars in Immunology
- Vol. 29, 41-48
Dendritic cells in host response to biologic scaffolds
- 1 February 2017
- Published by Elsevier in Seminars in Immunology
- Vol. 29, 41-48
Dendritic cells in host response to biologic scaffolds
- 15 August 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (4) , 1343-1352
Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events
TLR9 is an innate immune receptor important for recognizing DNA of host and foreign origin. A mechanism proposed to prevent excessive response to host DNA is the requirement for proteolytic cleavage of TLR9 in endosomes to generate a mature form of the receptor (TLR9471–1032). We previously described another cleavage event in the juxtamembrane region of the ectodomain that generated a dominant-negative form of TLR9. Thus, there are at least two independent cleavage events that regulate TLR9. In this study, we investigated whether an N-terminal fragment of TLR9 could be responsible for regulation of the mature or negative-regulatory form. We show that TLR9471–1032, corresponding to the proteolytically cleaved form, does not function on its own. Furthermore, activity is not rescued by coexpression of the N-terminal fragment (TLR91–440), inclusion of the hinge region (TLR9441–1032), or overexpression of UNC93B1, the last of which is critical for trafficking and cleavage of TLR9. TLR91–440 coimmunoprecipitates with full-length TLR9 and TLR9471–1032 but does not rescue the native glycosylation pattern; thus, inappropriate trafficking likely explains why TLR9471–1032 is nonfunctional. Lastly, we show that TLR9471–1032 is also a dominant-negative regulator of TLR9 signaling. Together, these data provide a new perspective on the complexity of TLR9 regulation by proteolytic cleavage and offer potential ways to inhibit activity through this receptor, which may dampen autoimmune inflammation.
- 15 August 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (4) , 1343-1352
Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events
TLR9 is an innate immune receptor important for recognizing DNA of host and foreign origin. A mechanism proposed to prevent excessive response to host DNA is the requirement for proteolytic cleavage of TLR9 in endosomes to generate a mature form of the receptor (TLR9471–1032). We previously described another cleavage event in the juxtamembrane region of the ectodomain that generated a dominant-negative form of TLR9. Thus, there are at least two independent cleavage events that regulate TLR9. In this study, we investigated whether an N-terminal fragment of TLR9 could be responsible for regulation of the mature or negative-regulatory form. We show that TLR9471–1032, corresponding to the proteolytically cleaved form, does not function on its own. Furthermore, activity is not rescued by coexpression of the N-terminal fragment (TLR91–440), inclusion of the hinge region (TLR9441–1032), or overexpression of UNC93B1, the last of which is critical for trafficking and cleavage of TLR9. TLR91–440 coimmunoprecipitates with full-length TLR9 and TLR9471–1032 but does not rescue the native glycosylation pattern; thus, inappropriate trafficking likely explains why TLR9471–1032 is nonfunctional. Lastly, we show that TLR9471–1032 is also a dominant-negative regulator of TLR9 signaling. Together, these data provide a new perspective on the complexity of TLR9 regulation by proteolytic cleavage and offer potential ways to inhibit activity through this receptor, which may dampen autoimmune inflammation.